The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism

Cancer Letters

Volumn 322, Issue 1, 2012, Pages 35-44

  Lampiasi, Nadia ^a   Azzolina, Antonina ^a   Umezawa, Kazuo ^b   Montalto, Giuseppe ^c   McCubrey, James A ^d   Cervello, Melchiorre ^a  

^a CNR   (Italy)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY OF PALERMO   (Italy)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

CD95 CD95L; Celecoxib; DHMEQ; Liver cancer cells; NF B

Indexed keywords

ACETYLCYSTEINE; CELECOXIB; DEHYDROXYMETHYLEPOXYQUINOMICIN; FAS ANTIGEN; FAS LIGAND; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GENE; GENE EXPRESSION; GENE SILENCING; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TBR3 GENE;

ACETYLCYSTEINE; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOHEXANONES; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS; SULFONAMIDES;

EID: 84861460801     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.008     Document Type: Article

References (46)

1. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 2006, 72:1605-1621.
2. Liu P., Kimmoun E., Legrand A., Sauvanet A., Degott C., Lardeux B., Bernuau D. Activation of NF-κB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J. Hepatol. 2002, 7:63-71.
3. Starenki D.V., Namba H., Saenko V.A., Ohtsuru A., Maeda S., Umezawa K., Yamashita S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethyl-epoxyquinomicin. Clin. Cancer Res. 2004, 10:6821-6829.
4. Nishimura D., Ishikawa H., Matsumoto K., Shibata H., Motoyoshi Y., Fukuta M., Kawashimo H., Goto T., Taura N., Ichikawa T., Hamasaki K., Nakao K., Umezawa K., Eguch K. DHMEQ, a novel NF-kB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int. J. Oncol. 2006, 29:713-719.
5. Poma P., Notarbartolo M., Labbozzetta M., Sanguedolce R., Alaimo A., Carina V., Maurici A., Cusimano A., Cervello M., D'Alessandro N. Antitumor effects of the novel NF-κB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int. J. Oncol. 2006, 28:923-930.
6. Lampiasi N., Azzolina A., D'Alessandro N., Umezawa K., McCubrey J.A., Montalto G., Cervello M. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Mol. Pharmacol. 2009, 76:290-300.
7. Kern M.A., Schubert D., Sahi D., Schöneweiss M.M., Moll I., Haugg A.M., Dienes H.P., Breuhahn K., Schirmacher P. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002, 36:885-894.
8. Foderà D., D'Alessandro N., Cusimano A., Poma P., Notarbartolo M., Lampiasi N., Montalto G., Cervello M. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann. N. Y. Acad. Sci. 2004, 1028:440-449.
9. Jendrossek V. Targeting apoptosis pathway by celecoxib in cancer. Cancer Lett. 2011, (Epub ahead of print).
10. Cervello M., Bachvarov D., Cusimano A., Sardina F., Azzolina A., Lampiasi N., Giannitrapani L., McCubrey J.A., Montalto G. COX-2-Dependent and COX-2-Independent mode of action of celecoxib in human liver cancer cells. Omics 2011, 6:383-392.
11. Cusimano A., Foderà D., D'Alessandro N., Lampiasi N., Azzolina A., Montalto G., Cervello M. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol. Ther. 2007, 6:1461-1468.
12. Pyrko P., Kardosh A., Liu Y.T., Soriano N., Xiong W., Chow R.H., Uddin J., Petasis N.A., Mircheff A.K., Farley R.A., Louie S.G., Chen T.C., Schönthal A.H. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celcoxib, a non-coxib analogue of celecoxib. Mol. Cancer Ther. 2007, 6:1262-1275.
13. Pyrko P., Soriano N., Kardish A., Liu Y.T., Uddin J., Petasis N.A., Hofman F.M., Chen C.S., Chen T.C., Schönthal A.H. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol. Cancer 2006, 18:5-19.
14. Kern M.A., Haugg A.M., Koch A.F., Schilling T., Breuhahn K., Walczak H., Fleischer B., Trautwein C., Michalski C., Schulze-Bergkamen H., Friess H., Stremmel W., Krammer P.H., Schirmacher P., Müller M. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 2006, 66:7059-7066.
15. Cusimano A., Azzolina A., Iovanna J., Bachvarov D., McCubrey J.A., D'Alessandro N., Montalto G., Cervello M. Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle 2010, 9:1399-1410.
16. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
17. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 2000, 6:513-551.
18. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
19. Huang H.L., Fang L.W., Lu S.P., Chou C.K., Luh T.Y., Lai M.Z. DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 2003, 22:8168-8177.
20. Suzuki Y., Sugiyama C., Ohno O., Umezawa K. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor. Tetrahedran 2004, 60:7061-7066.
21. Cervello M., Giannitrapani L., Labbozzetta M., Notarbartolo M., D'Alessandro N., Lampiasi N., Azzolina A., Montalto G. Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann. N. Y. Acad. Sci. 2004, 1028:432-439.
22. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Reg. 1984, 22:27-55.
23. Funakoshi-Tago M., Shimizu T., Tago K., Nakamura M., Itoh H., Sonoda Y., Kasahara T. Celecoxib potently inhibits TNF-α-induced nuclear translocation and activation of NF-κB. Biochem. Pharmacol. 2008, 76:662-671.
24. Bowie A., O'Neill L.A. Oxidative stress and nuclear factor-κB activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol. 2000, 59:13-23.
25. Han J., Goldstein L.A., Gastman B.R., Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 2006, 281:10153-10163.
26. Leu J.I., Dumont P., Hafey M., Murphy M.E., George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6:443-450.
27. Lin M.T., Lee R.C., Yang P.C., Ho F.M., Kuo M.L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. Biol. Chem. 2001, 276:48997-49002.
28. He Q., Luo X., Jin W., Huang Y., Reddy M.V., Reddy E.P., Sheikh M.S. Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. Oncogene 2008, 27:2656-2660.
29. Ohoka N., Yoshii S., Hattori T., Onozaki K., Hayashi H. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 2005, 24:1243-1255.
30. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011, 21:103-115.
31. Fang J., Nakamura H., Iyer A.K. Tumor-targeted induction of oxystress for cancer therapy. J. Drug Target 2007, 15:475-486.
32. Kumar B., Koul S., Khandrika L., Meacham R.B., Koul H.K. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2011, 68:1777-1785.
33. Yokouchi M., Hiramatsu N., Hayakawa K., Okamura M., Du S., Kasai A., Takano Y., Shitamura A., Shimada T., Yao J., Kitamura M. Involvement of selective oxygen species upstream of preapoptotic branches of unfolded protein responses. J. Biol. Chem. 2008, 283:4252-4360.
34. Cho H.Y., Thomas S., Golden E.B., Gaffney K.J., Hofman F.M., Chen T.C., Louie S.G., Petatis N.A., Schonthal A.H. Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. Cancer Lett. 2009, 282:87-97.
35. Tagawa Y., Hiramatsu N., Kasai A., Hayakawa K., Okamura M., Yao J., Kitamura M. Induction of apoptosis by cigarettes smoke via ROS-dependent endoplasmic reticulum stress and CAAT/enhancer-binding protein-homologous protein (CHOP). Free Rad. Biol. Med. 2008, 45:50-59.
36. Li J., Lee A.S. Stress induction of GRP78/BIP and its role in cancer. Curr. Mol. Med. 2006, 6:45-54.
37. 2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol. Cancer Ther. 2010, 9:1378-1395.
38. Iizaka T., Tsuji M., Oyamada H., Morio Y., Oguki K. Interaction between caspase-8 activation and endoplasmic reticulum stress in glycochenodeoxycholic acid-induced apoptotic HepG2 cells. Toxicology 2007, 241:146-156.
39. Liu J. HM. Shen, CN. Ong, Role of intracellular thiol depletion, mitochondrial dysfunction and reactive oxygen species in Salvia Miltiorrhiza-induced apoptosis in human hepatoma HepG2 cells. Life Sci. 2001, 69:1833-1850.
40. Yang Y., Zhao S., Song J. Caspase-dependent apoptosis and independent- poly(ADP-ribose) polymerase cleavage induced by transforming growth factor B1. Int. J. Biochem. Cell Biol. 2004, 36:223-234.
41. Fleischer B., Schulze-Bergkamen H., Schuchmann M., Weber A., Biesterfeld S., Müller M., Krammer P.H., Galle P.R. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int. J. Oncol. 2006, 28:25-32.
42. Zhang Z., La G.H., Sirica A.E. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004, 39:1028-1037.
43. Gao J., Jia W.D., Li J.S., Wang W., Xu G.L., Ma J.L., Ge Y.S., Yu J.H., Ren W.H., Liu W.B., Zhang C.H. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice. J. Int. Med. Res. 2010, 38:1423-1427.
44. Park M.A., Mitchell C., Zhang G., Yacoub A., Allegood J., Häussinger D., Reinehr R., Larner A., Spiegel S., Fisher P.B., Voelkel-Johnson C., Ogretmen B., Grant S., Dent P. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 2010, 70:6313-6324.
45. Bauer M.K., Vogt M., Los M., Siegel J., Wesselborg S., Schulze-Osthoff K. Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. Biol. Chem. 1998, 73:8048-8055.
46. Nakamura N., Nagano H., Sakon M., Yamamoto T., Ota H., Wada H. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J. Hepatol. 2007, 46:77-88.